Patient 2a: Stage 2 NK in the left eye[3,4]

Images show a neurotrophic corneal lesion from baseline through week 8 of an actual patient treated with OXERVATE® in a pivotal clinical trial. This is 1 patient's outcome. Results are not indicative of all patients in the clinical trial.



BASELINE

Patient Overview

Images are of a clinical trial patient with Stage 2 neurotrophic keratitis (NK) at baseline and week 8. Evaluations conducted by independent central reading center of the clinical images of corneal fluorescein staining. Not all patients in the trials achieved complete corneal healing. Individual results may vary.[1,2]

Back to Patient Cases | References

OXERVATE® is indicated for the treatment of neurotrophic keratitis.

Important Safety Information

WARNINGS AND PRECAUTIONS

Use with Contact Lens

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

Please read the full Prescribing Information for OXERVATE, available from your Dompé representative.

Prescribing Information

oxervate® (cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

Patient 2a: Stage 2 NK in the left eye[3,4]

Images show a neurotrophic corneal lesion from baseline through week 8 of an actual patient treated with OXERVATE® in a pivotal clinical trial. This is 1 patient's outcome. Results are not indicative of all patients in the clinical trial.



WEEK 8

Patient Overview

Images are of a clinical trial patient with Stage 2 neurotrophic keratitis (NK) at baseline and week 8. Evaluations conducted by independent central reading center of the clinical images of corneal fluorescein staining. Not all patients in the trials achieved complete corneal healing. Individual results may vary.[1,2]

Back to Patient Cases | References

OXERVATE® is indicated for the treatment of neurotrophic keratitis.

Important Safety Information

WARNINGS AND PRECAUTIONS

Use with Contact Lens

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

Please read the full Prescribing Information for OXERVATE, available from your Dompé representative.

Prescribing Information

oxervate® (cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

Done

Patient 2a[4]

Patient information*

33-year-old female

Eye: Left, OS

Treatment-related adverse events†

None[4]

†As recorded by the investigator; relationship to study treatment recorded as possible, probable, or highly probable.

Study

NGF0214

Investigator-determined etiology

Herpes zoster virus and diabetes

Diagnosis

NK Stage 2

Evaluation of complete corneal healing

Complete corneal healing, defined as absence of staining of the corneal lesion and no persistent staining in the rest of the cornea, at 8 weeks of treatment.[3,5]

IMPORTANT NOTE: Each clinical trial participant's experience on treatment is unique. Individual results may vary.

*The information depicted is what was collected as part of the requirements of the clinical trials. This is not an all-inclusive medical history of the patient.[1,2]